南方医科大学学报

南方医科大学学报 ›› 2021, Vol. 41 ›› Issue (12): 1885-1891.doi: 10.12122/j.issn.1673-4254.2021.12.19

• • 上一篇    下一篇

高表达miR-3682-3p是肝细胞癌患者的不良预后因素

刘绍华，温莹浩，全 兵，蔺 军，朱泽文，汤江林，韩思源   

  1. 萍乡市人民医院普外科，肿瘤科，重症监护室，江西 萍乡 337000；南方医科大学中西医结合医院肿瘤中心广东 广州 510220；东莞市松山湖中心医院肿瘤科，广东 东莞 523000
  • 出版日期:2021-12-20 发布日期:2022-01-05

High expression of miR-3682-3p is an unfavorable prognostic factor of hepatocellular carcinoma

LIU Shaohua, WEN Yinghao, QUAN Bing, LIN Jun, ZHU Zewen, TANG Jianglin, HAN Siyuan   

  1. Department of General Surgery, Department of Oncology, Intensive Care Unit, Pingxiang People's Hospital, Pingxiang 337000, China; Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510220, China; Department of Oncology, Songshanhu Central Hospital of Dongguan, Dongguan 523000, China
  • Online:2021-12-20 Published:2022-01-05

RichHTML

47

PDF

419

摘要： 目的 分析miR-3682-3p在HCC中的表达及其与临床参数和预后的相关性。方法 生物信息学分析miR-3682-3p在HCC中的表达以及与生存相关性；实时荧光定量PCR和原位杂交分别检测miR-3682-3p（miR-3682）在18对HCC与癌旁新鲜肝组织以及90对石蜡包埋HCC及其癌旁组织中的表达差异。统计分析miR-3682-3p在HCC中的表达与患者临床参数和预后之间的关系。利用多因素回归分析探讨miR-3682-3p表达作为肝细胞癌预后独立因素的可能性。结果 生物信息分析显示，miR-3682-3p在HCC组织中高表达，且与HCC患者综合生存时间有统计学关联（χ2=8.793，P<0.001）。实时荧光定量PCR分析18组配对的HCC和癌旁肝组织显示，miR-3682-3p在癌组织中表达明显上调（t=3.073，P=0.007）。原位杂交分析90组配对的HCC和癌旁组织中miR-3682-3p的表达，显示其在癌与癌旁组织的细胞浆中表达，并且在癌组织中表达上调（t=2.659，P=0.009）。miR-3682-3p表达的高低在美国癌症联合委员会（AJCC）第八版分期（χ2=4.272，P=0.039）、HBV表面抗原状态（χ2=5.143，P= 0.023）、复发（χ2=4.593，P=0.032）、肿瘤大小（χ2=4.580，P=0.032）和Edmondson-Steiner分级（χ2=4.068，P=0.044）方面差异存在统计学意义；Kaplan-Meier分析显示，miR-3682-3p表达越高，患者总生存时间（Log rank χ2=4.169，P=0.041）和无病生存时间（Log rank χ2=4.078，P=0.043）越短。多变量分析显示，miR-3682-3p表达是评估HCC患者预后独立因子。结论 miR-3682-3p在HCC组织中表达上调，是促进HCC发病和预后不良的重要因子。

关键词: 肝细胞癌；miR-3682-3p；预后

Abstract: Objective To investigate the expression of miR-3682-3p in hepatocellular carcinoma (HCC) and its correlation with clinical parameters and prognosis of HCC. Methods We conducted a bioinformatics analysis of the expression of miR-3682-3p in HCC and its correlation with the patients' survival, and examined its expression in 18 pairs of fresh and 90 pairs of paraffin-embedded HCC and adjacent tissues using real-time fluorescence quantitative PCR and in situ hybridization, respectively. The correlation of miR-3682-3p expression in HCC with the clinical parameters and prognosis of the patients was analyzed. Multivariate regression analysis was used to explore the possibility of miR-3682-3p expression as an independent prognostic factor of HCC. Results Bioinformatics analysis showed that miR-3682-3p was highly expressed in HCC and significantly correlated with the survival time of HCC patients (χ2=8.793, P<0.001). The expression of miR-3682-3p was significantly up-regulated in fresh HCC tissues as compared with the adjacent liver tissues (t=3.073，P=0.007). In paraffin-embedded samples, in situ hybridization revealed positive miR-3682-3p expression in the cytoplasm of HCC and adjacent tissues, and its expression was signifcantly up-regulated in HCC tissues (t=2.659, P=0.009). The expression level of miR-3682-3p was significantly correlated with American Joint Commission on Cancer (AJCC; 8th edition) stage (χ2=4.272, P= 0.039), HBV surface antigen status (χ2=5.143, P=0.023), recurrence (χ2=4.593，P=0.032), tumor size (χ2=4.580, P=0.032) and Edmondson Steiner grade (χ2=4.068, P=0.044). Kaplan-Meier analysis showed that a higher expression of miR-3682-3p was associated with a shorter overall survival time (χ2=4.169, P=0.041) and disease-free survival time (χ2=4.078, P=0.043) of the patients. Multivariate analysis suggested that miR-3682-3p expression was an independent predictor of the prognosis of HCC patients. Conclusion MiR-3682-3p is up-regulated in HCC to serve as a significant factor that contributes to the occurrence and a poor prognosis of HCC.

Key words: hepatocellular carcinoma; miR-3682-3p; prognostic factor